Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:00 pm EST
Share
Arcellx, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 14.96 million. Net loss was USD 39.34 million compared to USD 92.87 million a year ago. Basic loss per share from continuing operations was USD 0.81 compared to USD 2.12 a year ago. Diluted loss per share from continuing operations was USD 0.81 compared to USD 2.12 a year ago.
For the nine months, sales was USD 47.17 million. Net loss was USD 90.53 million compared to USD 149.69 million a year ago. Basic loss per share from continuing operations was USD 1.89 compared to USD 4.43 a year ago. Diluted loss per share from continuing operations was USD 1.89 compared to USD 4.43 a year ago.
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Companyâs lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).